This study focused on evaluating the degradation potential of CTSB on amyloid fibrils with varying clustering tendencies, associated with Alzheimer’s and Parkinson’s diseases, hemodialysis, and lysozyme amyloidosis. This evidence concerns the gene LYZ and Parkinson disease.